AGIX - IMO the key factors going forward for 1067 are:
a) The one case of liver failure.
b) The fact that AZN doesn't have a diabetes program.
The analysts are making hay of the liver enzymes with lots of comparisons to Rezulin (diabetes drug pulled from the market due to liver failure) - but Rezulin had much greater incidence of elevated enzymes and it had 2 liver failures in smaller patient pop and undoubtedly a smaller time on drug. Is the liver failure a cause for concern? Yep. Is it remotely comparible to Rezulin - not really.
Market Data 
Markets 
AI
